With a growing number of coronavirus COVID-19 cases worldwide, U.S.-based biotech company Moderna is getting closer to revealing late-stage data on coronavirus vaccine candidates.
Moderna announced that it has collected enough data for an interim analysis of late-stage trials of the coronavirus vaccine, adding that data analysis will help the company find the vaccine’s efficacy. According to the U.S. company, this information is ready to be submitted to an independent data safety monitoring committee, which is tasked with reviewing the findings and providing recommendations. However, Moderna has not yet published a release date for efficacy data. Coronavirus vaccine candidate.
On Monday, Pfizer Inc. and BioNTech SE revealed on Monday that their vaccine candidate was found to be more than 90% effective in preventing COVID-19. Pfizer Chairman and CEO Albert Bourla said, “Today is a good day for science and humanity. The first set of results from a phase 3 COVID-19 vaccine trial provides early evidence of our vaccine’s ability to prevent COVID-19.”
Meanwhile, AIIMS director Dr. Randeep Guleria said Wednesday (November 11) that the cryogenic temperatures of minus 70 degrees Celsius needed to store a potential COVID-19 vaccine developed by Pfizer are in India, especially in a small town where it is not easy to maintain a cold chain facility. And rural areas.
Most vaccines in India should be stored at temperatures between 2 and 8 degrees Celsius. Guleria said the lowest temperature at which vaccines can be stored to keep the chain cold in most regions is -25 degrees Celsius.